Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed
reference product Epogen®/Procrit® when applied subcutaneously. This study is intended to
generate data supporting that the efficacy and safety under treatment with HX575 and
Epogen®/Procrit® are comparable.